We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
METHYLPHENIDATE SANDOZ XR (Sandoz Pty Ltd)
Product name
METHYLPHENIDATE SANDOZ XR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
111 (255 working days)
Active ingredients
methylphenidate hydrochloride
Registration type
New generic medicine
Indication
METHYLPHENIDATE SANDOZ XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.